{"id":94546,"topic":"ai","source":"Drug Target Review","title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","url_hash":"6c09300175695d4a2d3cdefad8bb9b8800bb635a","author":"","summary":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease Drug Target Review","content":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.\nInsilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.\nThe preclinical candidate, ISM1354, is being developed for potential use in obesity and obesity-related disorders including Type 2 diabetes. Insilico said it could also have applications in cardiovascular diseases associated with obesity, including heart failure.\nThe announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies. The approach is intended to support weight loss while helping to preserve muscle mass, a key consideration as populations age and concerns about sarcopenia grow.\nGenerative AI used throughout drug discovery process\nInsilico said ISM1354 was developed using its Chemistry42 generative chemistry platform, which incorporates multiple prediction and optimisation tools into the drug discovery process.\nThe company used protein-ligand structures and information about key molecular interactions to optimise potency and selectivity while screening for potential safety issues. A drug-induced liver injury prediction model was used to filter molecules early in the process, followed by free energy perturbation modelling to predict and rank binding affinity.\nResearchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate.\n“Generative AI is demonstrating immense potential in cracking complex drug discovery challenges,” said Dr Feng Ren, Co-CEO and CSO of Insilico Medicine. “Given the structural complexity and intricate functional mechanisms of GIPR, the identification of viable small-molecule GIPR antagonists and the optimisation of their drug-like properties remain major challenges in drug development However, by leveraging the highly efficient molecular generation and optimisation capabilities of our Pharma.AI platform, we successfully overcame these bottlenecks in a very short time and nominated the next-generation GIPR antagonist, ISM1354.”\nPreclinical studies show high oral bioavailability\nAccording to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent.\nAt the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential.\nSafety testing also produced differentiated results. Insilico reported substantially weaker inhibition of OATP1B1 than the benchmark compound, alongside a wider hepatocyte safety margin. ISM1354 had minimal effects on cell viability at concentrations of up to 200 μM while the benchmark compound showed cytotoxicity at approximately 25 μM in human hepatocytes and 20 μM in monkey hepatocytes.\nIn a non-GLP monkey toxicology assessment, ISM1354 was generally well tolerated with no significant toxicity findings reported. Insilico estimated an approximately 45-fold margin of safety and said the results supported progression to GLP toxicology studies.\nResearch aims to address weight loss and muscle preservation\nThe company previously nominated another GIPR antagonist, ISM0676, which it said produced up to 31.3 percent weight loss when combined with semaglutide in humanised mouse models. Insilico said ISM1354 retained robust weight-loss efficacy while improving pharmacokinetic and safety characteristics.\n“Obesity is not an isolated health issue; it is a trigger for many diseases, and lipid metabolism disorder itself is a core hallmark of biological ageing. I believe that GLP-1 therapies are poised to become the first ‘longevity drugs’ that can be popularised on a large scale, which is a massive opportunity that cannot be measured by money alone.” said Dr Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine. “However, we absolutely cannot trade the decline in body weight at the expense of physical vitality and muscle mass, and this has been a long-standing pain point in the industry.”\nThe company said the nomination brings its total number of preclinical candidates nominated since 2021 to 34.","image_url":"https://dft2fymcn9opj.cloudfront.net/Pictures/1024x536/9/6/7/22967_shutterstock_2661773161_633968.jpg","lang":"en","published_at":"2026-10-02T08:37:57+00:00","fetched_at":"2026-10-02T09:15:05+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}},"news_item":{"id":94546,"canonical_url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","source_url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","source_name":"Drug Target Review","author":null,"published_at":"2026-10-02T08:37:57+00:00","locale":"en","topic":"ai","tags":[],"rss_summary":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease Drug Target Review","full_text":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.\nInsilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.\nThe preclinical candidate, ISM1354, is being developed for potential use in obesity and obesity-related disorders including Type 2 diabetes. Insilico said it could also have applications in cardiovascular diseases associated with obesity, including heart failure.\nThe announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies. The approach is intended to support weight loss while helping to preserve muscle mass, a key consideration as populations age and concerns about sarcopenia grow.\nGenerative AI used throughout drug discovery process\nInsilico said ISM1354 was developed using its Chemistry42 generative chemistry platform, which incorporates multiple prediction and optimisation tools into the drug discovery process.\nThe company used protein-ligand structures and information about key molecular interactions to optimise potency and selectivity while screening for potential safety issues. A drug-induced liver injury prediction model was used to filter molecules early in the process, followed by free energy perturbation modelling to predict and rank binding affinity.\nResearchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate.\n“Generative AI is demonstrating immense potential in cracking complex drug discovery challenges,” said Dr Feng Ren, Co-CEO and CSO of Insilico Medicine. “Given the structural complexity and intricate functional mechanisms of GIPR, the identification of viable small-molecule GIPR antagonists and the optimisation of their drug-like properties remain major challenges in drug development However, by leveraging the highly efficient molecular generation and optimisation capabilities of our Pharma.AI platform, we successfully overcame these bottlenecks in a very short time and nominated the next-generation GIPR antagonist, ISM1354.”\nPreclinical studies show high oral bioavailability\nAccording to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent.\nAt the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential.\nSafety testing also produced differentiated results. Insilico reported substantially weaker inhibition of OATP1B1 than the benchmark compound, alongside a wider hepatocyte safety margin. ISM1354 had minimal effects on cell viability at concentrations of up to 200 μM while the benchmark compound showed cytotoxicity at approximately 25 μM in human hepatocytes and 20 μM in monkey hepatocytes.\nIn a non-GLP monkey toxicology assessment, ISM1354 was generally well tolerated with no significant toxicity findings reported. Insilico estimated an approximately 45-fold margin of safety and said the results supported progression to GLP toxicology studies.\nResearch aims to address weight loss and muscle preservation\nThe company previously nominated another GIPR antagonist, ISM0676, which it said produced up to 31.3 percent weight loss when combined with semaglutide in humanised mouse models. Insilico said ISM1354 retained robust weight-loss efficacy while improving pharmacokinetic and safety characteristics.\n“Obesity is not an isolated health issue; it is a trigger for many diseases, and lipid metabolism disorder itself is a core hallmark of biological ageing. I believe that GLP-1 therapies are poised to become the first ‘longevity drugs’ that can be popularised on a large scale, which is a massive opportunity that cannot be measured by money alone.” said Dr Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine. “However, we absolutely cannot trade the decline in body weight at the expense of physical vitality and muscle mass, and this has been a long-standing pain point in the industry.”\nThe company said the nomination brings its total number of preclinical candidates nominated since 2021 to 34.","excerpt":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4580 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","summary":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.","source":"Drug Target Review","date":"2026-10-02T08:37:57+00:00","content":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.\nInsilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.\nThe preclinical candidate, ISM1354, is being developed for potential use in obesity and obesity-related disorders including Type 2 diabetes. Insilico said it could also have applications in cardiovascular diseases associated with obesity, including heart failure.\nThe announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies. The approach is intended to support weight loss while helping to preserve muscle mass, a key consideration as populations age and concerns about sarcopenia grow.\nGenerative AI used throughout drug discovery process\nInsilico said ISM1354 was developed using its Chemistry42 generative chemistry platform, which incorporates multiple prediction and optimisation tools into the drug discovery process.\nThe company used protein-ligand structures and information about key molecular interactions to optimise potency and selectivity while screening for potential safety issues. A drug-induced liver injury prediction model was used to filter molecules early in the process, followed by free energy perturbation modelling to predict and rank binding affinity.\nResearchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate.\n“Generative AI is demonstrating immense potential in cracking complex drug discovery challenges,” said Dr Feng Ren, Co-CEO and CSO of Insilico Medicine. “Given the structural complexity and intricate functional mechanisms of GIPR, the identification of viable small-molecule GIPR antagonists and the optimisation of their drug-like properties remain major challenges in drug development However, by leveraging the highly efficient molecular generation and optimisation capabilities of our Pharma.AI platform, we successfully overcame these bottlenecks in a very short time and nominated the next-generation GIPR antagonist, ISM1354.”\nPreclinical studies show high oral bioavailability\nAccording to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent.\nAt the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential.\nSafety testing also produced differentiated results. Insilico reported substantially weaker inhibition of OATP1B1 than the benchmark compound, alongside a wider hepatocyte safety margin. ISM1354 had minimal effects on cell viability at concentrations of up to 200 μM while the benchmark compound showed cytotoxicity at approximately 25 μM in human hepatocytes and 20 μM in monkey hepatocytes.\nIn a non-GLP monkey toxicology assessment, ISM1354 was generally well tolerated with no significant toxicity findings reported. Insilico estimated an approximately 45-fold margin of safety and said the results supported progression to GLP toxicology studies.\nResearch aims to address weight loss and muscle preservation\nThe company previously nominated another GIPR antagonist, ISM0676, which it said produced up to 31.3 percent weight loss when combined with semaglutide in humanised mouse models. Insilico said ISM1354 retained robust weight-loss efficacy while improving pharmacokinetic and safety characteristics.\n“Obesity is not an isolated health issue; it is a trigger for many diseases, and lipid metabolism disorder itself is a core hallmark of biological ageing. I believe that GLP-1 therapies are poised to become the first ‘longevity drugs’ that can be popularised on a large scale, which is a massive opportunity that cannot be measured by money alone.” said Dr Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine. “However, we absolutely cannot trade the decline in body weight at the expense of physical vitality and muscle mass, and this has been a long-standing pain point in the industry.”\nThe company said the nomination brings its total number of preclinical candidates nominated since 2021 to 34.","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4580 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/94546","export_markdown":"/api/items/94546/export?format=markdown","export_json":"/api/items/94546/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article"},"formats":{"full":{"id":94546,"title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","source":"Drug Target Review","author":null,"published_at":"2026-10-02T08:37:57+00:00","locale":"en","topic":"ai","tags":[],"excerpt":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.","full_text":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.\nInsilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.\nThe preclinical candidate, ISM1354, is being developed for potential use in obesity and obesity-related disorders including Type 2 diabetes. Insilico said it could also have applications in cardiovascular diseases associated with obesity, including heart failure.\nThe announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies. The approach is intended to support weight loss while helping to preserve muscle mass, a key consideration as populations age and concerns about sarcopenia grow.\nGenerative AI used throughout drug discovery process\nInsilico said ISM1354 was developed using its Chemistry42 generative chemistry platform, which incorporates multiple prediction and optimisation tools into the drug discovery process.\nThe company used protein-ligand structures and information about key molecular interactions to optimise potency and selectivity while screening for potential safety issues. A drug-induced liver injury prediction model was used to filter molecules early in the process, followed by free energy perturbation modelling to predict and rank binding affinity.\nResearchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate.\n“Generative AI is demonstrating immense potential in cracking complex drug discovery challenges,” said Dr Feng Ren, Co-CEO and CSO of Insilico Medicine. “Given the structural complexity and intricate functional mechanisms of GIPR, the identification of viable small-molecule GIPR antagonists and the optimisation of their drug-like properties remain major challenges in drug development However, by leveraging the highly efficient molecular generation and optimisation capabilities of our Pharma.AI platform, we successfully overcame these bottlenecks in a very short time and nominated the next-generation GIPR antagonist, ISM1354.”\nPreclinical studies show high oral bioavailability\nAccording to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent.\nAt the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential.\nSafety testing also produced differentiated results. Insilico reported substantially weaker inhibition of OATP1B1 than the benchmark compound, alongside a wider hepatocyte safety margin. ISM1354 had minimal effects on cell viability at concentrations of up to 200 μM while the benchmark compound showed cytotoxicity at approximately 25 μM in human hepatocytes and 20 μM in monkey hepatocytes.\nIn a non-GLP monkey toxicology assessment, ISM1354 was generally well tolerated with no significant toxicity findings reported. Insilico estimated an approximately 45-fold margin of safety and said the results supported progression to GLP toxicology studies.\nResearch aims to address weight loss and muscle preservation\nThe company previously nominated another GIPR antagonist, ISM0676, which it said produced up to 31.3 percent weight loss when combined with semaglutide in humanised mouse models. Insilico said ISM1354 retained robust weight-loss efficacy while improving pharmacokinetic and safety characteristics.\n“Obesity is not an isolated health issue; it is a trigger for many diseases, and lipid metabolism disorder itself is a core hallmark of biological ageing. I believe that GLP-1 therapies are poised to become the first ‘longevity drugs’ that can be popularised on a large scale, which is a massive opportunity that cannot be measured by money alone.” said Dr Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine. “However, we absolutely cannot trade the decline in body weight at the expense of physical vitality and muscle mass, and this has been a long-standing pain point in the industry.”\nThe company said the nomination brings its total number of preclinical candidates nominated since 2021 to 34.","reading_time_min":3,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4580 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}},"actions":{"read":"/item/94546","export_markdown":"/api/items/94546/export?format=markdown","export_json":"/api/items/94546/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article"}},"digest":{"id":94546,"title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","source":"Drug Target Review","topic":"ai","published_at":"2026-10-02T08:37:57+00:00","excerpt":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 4580 characters.","reading_time_min":3,"cluster_id":null},"card":{"display_title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","subtitle":"Drug Target Review · 2026-10-02","summary":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.…","badges":["quality:high"],"links":{"read":"/item/94546","original":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","diagnose":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article"},"quality_warning":null},"export":{"title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease - Drug Target Review","url":"https://www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","summary":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies. Insilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.","source":"Drug Target Review","date":"2026-10-02T08:37:57+00:00","content":"Developed using Insilico’s Chemistry42 platform, ISM1354 demonstrated oral bioavailability of up to 104 percent across multiple species and an approximately 45-fold safety margin in non-GLP monkey toxicology studies.\nInsilico Medicine has nominated an artificial intelligence-designed small-molecule candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as the company seeks to develop new approaches to obesity and related metabolic diseases.\nThe preclinical candidate, ISM1354, is being developed for potential use in obesity and obesity-related disorders including Type 2 diabetes. Insilico said it could also have applications in cardiovascular diseases associated with obesity, including heart failure.\nThe announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies. The approach is intended to support weight loss while helping to preserve muscle mass, a key consideration as populations age and concerns about sarcopenia grow.\nGenerative AI used throughout drug discovery process\nInsilico said ISM1354 was developed using its Chemistry42 generative chemistry platform, which incorporates multiple prediction and optimisation tools into the drug discovery process.\nThe company used protein-ligand structures and information about key molecular interactions to optimise potency and selectivity while screening for potential safety issues. A drug-induced liver injury prediction model was used to filter molecules early in the process, followed by free energy perturbation modelling to predict and rank binding affinity.\nResearchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate.\n“Generative AI is demonstrating immense potential in cracking complex drug discovery challenges,” said Dr Feng Ren, Co-CEO and CSO of Insilico Medicine. “Given the structural complexity and intricate functional mechanisms of GIPR, the identification of viable small-molecule GIPR antagonists and the optimisation of their drug-like properties remain major challenges in drug development However, by leveraging the highly efficient molecular generation and optimisation capabilities of our Pharma.AI platform, we successfully overcame these bottlenecks in a very short time and nominated the next-generation GIPR antagonist, ISM1354.”\nPreclinical studies show high oral bioavailability\nAccording to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent.\nAt the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential.\nSafety testing also produced differentiated results. Insilico reported substantially weaker inhibition of OATP1B1 than the benchmark compound, alongside a wider hepatocyte safety margin. ISM1354 had minimal effects on cell viability at concentrations of up to 200 μM while the benchmark compound showed cytotoxicity at approximately 25 μM in human hepatocytes and 20 μM in monkey hepatocytes.\nIn a non-GLP monkey toxicology assessment, ISM1354 was generally well tolerated with no significant toxicity findings reported. Insilico estimated an approximately 45-fold margin of safety and said the results supported progression to GLP toxicology studies.\nResearch aims to address weight loss and muscle preservation\nThe company previously nominated another GIPR antagonist, ISM0676, which it said produced up to 31.3 percent weight loss when combined with semaglutide in humanised mouse models. Insilico said ISM1354 retained robust weight-loss efficacy while improving pharmacokinetic and safety characteristics.\n“Obesity is not an isolated health issue; it is a trigger for many diseases, and lipid metabolism disorder itself is a core hallmark of biological ageing. I believe that GLP-1 therapies are poised to become the first ‘longevity drugs’ that can be popularised on a large scale, which is a massive opportunity that cannot be measured by money alone.” said Dr Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine. “However, we absolutely cannot trade the decline in body weight at the expense of physical vitality and muscle mass, and this has been a long-standing pain point in the industry.”\nThe company said the nomination brings its total number of preclinical candidates nominated since 2021 to 34.","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.drugtargetreview.com/news/insilico-medicine-nominates-ai-designed-ism1354-gipr-antagonist-for-obesity/2136626.article","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4580 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4580 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4580,"summary_length":475,"usable_text_length":4580,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4580,"summary_length":475}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}